ZY Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Zymergen Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Zymergen Inc. (NASDAQ: ZY) to Ginkgo Bioworks for 0.9179 Ginkgo shares for each Zymergen share is fair to Zymergen shareholders.

Halper Sadeh encourages Zymergen shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

The investigation concerns whether Zymergen and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Zymergen shareholders; (2) determine whether Ginkgo Bioworks is underpaying for Zymergen; and (3) disclose all material information necessary for Zymergen shareholders to adequately assess and value the merger consideration. On behalf of Zymergen shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Zymergen shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.